Affordable Access

deepdyve-link deepdyve-link
Publisher Website

First-line treatment of chronic myeloid leukaemia.

Authors
Type
Published Article
Journal
Therapeutic advances in hematology
Publication Date
Volume
1
Issue
1
Pages
15–22
Identifiers
DOI: 10.1177/2040620710387981
PMID: 23556068
Source
Medline
Keywords
License
Unknown

Abstract

Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid Leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

Statistics

Seen <100 times